Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Stoke Therapeutics Inc (NASDAQ: STOK) closed at $18.49 down -0.11% from its previous closing price of $18.51. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 1.38 million shares were traded. STOK stock price reached its highest trading level at $18.84 during the session, while it also had its lowest trading level at $18.05.
Ratios:
For a deeper understanding of Stoke Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.57. For the most recent quarter (mrq), Quick Ratio is recorded 6.98 and its Current Ratio is at 6.98. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On December 20, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $24.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’25 when Allan Jonathan sold 13,712 shares for $15.00 per share. The transaction valued at 205,680 led to the insider holds 19,631 shares of the business.
JONATHAN ALLAN bought 13,712 shares of STOK for $185,523 on Aug 13 ’25. On Aug 01 ’25, another insider, Ticho Barry, who serves as the CHIEF MEDICAL OFFICER of the company, sold 4,504 shares for $12.82 each. As a result, the insider received 57,724 and left with 16,775 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1013203904 and an Enterprise Value of 770143232. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.07 while its Price-to-Book (P/B) ratio in mrq is 3.02. Its current Enterprise Value per Revenue stands at 3.853 whereas that against EBITDA is 18.219.
Stock Price History:
The Beta on a monthly basis for STOK is 1.13, which has changed by 0.24932432 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $18.60, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 44.12%, while the 200-Day Moving Average is calculated to be 72.43%.
Shares Statistics:
For the past three months, STOK has traded an average of 709.08K shares per day and 1114240 over the past ten days. A total of 54.72M shares are outstanding, with a floating share count of 45.93M. Insiders hold about 16.18% of the company’s shares, while institutions hold 108.25% stake in the company. Shares short for STOK as of 1753920000 were 11430622 with a Short Ratio of 16.12, compared to 1751241600 on 11534286. Therefore, it implies a Short% of Shares Outstanding of 11430622 and a Short% of Float of 25.330000000000002.
Earnings Estimates
At present, 9.0 analysts are actively evaluating the performance of Stoke Therapeutics Inc (STOK) in the stock market.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.54 and low estimates of -$0.81.
Analysts are recommending an EPS of between $0.48 and -$0.1 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is -$2.92, with 9.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $6.06M this quarter.It ranges from a high estimate of $12M to a low estimate of $3M. As of the current estimate, Stoke Therapeutics Inc’s year-ago sales were $4.89MFor the next quarter, 10 analysts are estimating revenue of $5.47M. There is a high estimate of $11M for the next quarter, whereas the lowest estimate is $3M.
A total of 11 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $205.8M, while the lowest revenue estimate was $178.39M, resulting in an average revenue estimate of $185.57M. In the same quarter a year ago, actual revenue was $36.55M
